Literature DB >> 20932224

Oral salmon calcitonin--pharmacology in osteoporosis.

Kim Henriksen1, Anne-Christine Bay-Jensen, Claus Christiansen, Morten Asser Karsdal.   

Abstract

IMPORTANCE OF THE FIELD: Osteoporosis is a slow progressive disease with develops over decades, and where intervention is needed for an extended number of years. This highlights the need for safe intervention possibilities, which have sustained beneficial effects post-treatment. AREAS COVERED IN THIS REVIEW: Articles on salmon calcitonin appearing on Pubmed from 1960 until today, with focus on a newly developed oral formulation showing increased exposure and efficacy compared with nasal formulation is reviewed. The second half focuses on long-term phenomena, such as bone quality and resolution effects. The final part discusses potential additional benefits of salmon calcitonin. WHAT THE READER WILL GAIN: Insight into the clinical development of an orally formulated peptide, as well as a detailed understanding of why this approach could revive salmon calcitonin as a treatment for osteoporosis. TAKE HOME MESSAGE: The oral formulation of salmon calcitonin provides additional benefits and increased efficacy on bone based on Phase I and II clinical trials data, as compared with the nasal formulation. Hence, the results on the ongoing Phase III fracture trial are awaited with great interest.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20932224     DOI: 10.1517/14712598.2010.526104

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  14 in total

1.  Generating orally active galanin analogues with analgesic activities.

Authors:  Charles R Robertson; Timothy H Pruess; Erin Grussendorf; H Steve White; Grzegorz Bulaj
Journal:  ChemMedChem       Date:  2012-02-28       Impact factor: 3.466

2.  Oral calcitonin.

Authors:  Michael J Maricic
Journal:  Curr Osteoporos Rep       Date:  2012-03       Impact factor: 5.096

Review 3.  Structure of Class B GPCRs: new horizons for drug discovery.

Authors:  Andrea Bortolato; Andrew S Doré; Kaspar Hollenstein; Benjamin G Tehan; Jonathan S Mason; Fiona H Marshall
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

Review 4.  Individualizing osteoporosis therapy.

Authors:  S Silverman; C Christiansen
Journal:  Osteoporos Int       Date:  2012-01-05       Impact factor: 4.507

Review 5.  Lessons learned from the clinical development of oral peptides.

Authors:  Morten Asser Karsdal; Bente Juul Riis; Nozer Mehta; William Stern; Ehud Arbit; Claus Christiansen; Kim Henriksen
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

6.  NMR characterization of monomeric and oligomeric conformations of human calcitonin and its interaction with EGCG.

Authors:  Rui Huang; Subramanian Vivekanandan; Jeffrey R Brender; Yuki Abe; Akira Naito; Ayyalusamy Ramamoorthy
Journal:  J Mol Biol       Date:  2011-12-17       Impact factor: 5.469

7.  Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizations.

Authors:  Saida Mebarek; Abdelkarim Abousalham; David Magne; Le Duy Do; Joanna Bandorowicz-Pikula; Slawomir Pikula; René Buchet
Journal:  Int J Mol Sci       Date:  2013-03-01       Impact factor: 5.923

8.  Hormone-stimulated modulation of endocytic trafficking in osteoclasts.

Authors:  Gudrun Stenbeck; Kevin M Lawrence; Anthony P Albert
Journal:  Front Endocrinol (Lausanne)       Date:  2012-08-22       Impact factor: 5.555

9.  The inhibitory effect of salmon calcitonin on tri-iodothyronine induction of early hypertrophy in articular cartilage.

Authors:  Pingping Chen-An; Kim Vietz Andreassen; Kim Henriksen; Yadong Li; Morten Asser Karsdal; Anne-Christine Bay-Jensen
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

10.  Oral calcitonin.

Authors:  Ronald C Hamdy; Dane N Daley
Journal:  Int J Womens Health       Date:  2012-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.